* Onconova Therapeutics Inc reported a quarterly adjusted loss of 19 cents​​ per share for the quarter ended in December, higher than the same quarter last year, when the company reported EPS of -26 cents. The mean expectation of three analysts for the quarter was for a loss of 25 cents per share. Wall Street expected results to range from -28 cents to -23 cents per share.

* Revenue held steady 0% to $56.00 thousand from a year ago; analysts expected $65.33 thousand.

* Onconova Therapeutics Inc's reported EPS for the quarter was a loss of 19 cents​.

* The company reported a quarterly loss of $4.18 million.

* Onconova Therapeutics Inc shares had held steady so far this quarter and gained 35.5% so far this year.

FORECAST CHANGES

* The mean earnings estimate of analysts was unchanged in the last three months.​

* In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."

* The average consensus recommendation for the pharmaceuticals peer group is also "buy"

Wall Street's median 12-month price target for Onconova Therapeutics Inc is $7.00 This summary was machine generated from LSEG data April 1 at 09:52 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING ESTIMATE ACTUAL BEAT, MET,

MISSED

Dec. 31 2023 -0.25 -0.19 Beat

Sep. 30 2023 -0.29 -0.23 Beat

Jun. 30 2023 -0.31 -0.20 Beat

Mar. 31 2023 -0.30 -0.28 Beat